BCYCBicycle Therapeutics plc

$374M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-68.8% YoY

Gross Profit

-$68M-2332.5% margin

Operating Income

-$87M-2965.8% margin

Net Income

-$79M-2703.8% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

-70.7%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$73M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$832M

Total Liabilities

$163M

Stockholders' Equity

$669M

Cash & Equivalents

$721M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$9M	-68.8%
Gross Profit	-$68M	$9M	-827.6%
Operating Income	-$87M	-$47M	-85.7%
Net Income	-$79M	-$40M	-98.3%

BCYC Q2 2025 Earnings — Bicycle Therapeutics plc Revenue & Financial Results | Market Cap Arena